

COURSE FACULTY, IAS–USA STAFF, SCIENTIFIC LEADERSHIP BOARD, AND GOVERNANCE BOARD

FINANCIAL RELATIONSHIPS WITH INELIGIBLE COMPANIES

In the interest of maintaining the independence of its CME activities and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, course faculty, Scientific Leadership Board, and program staff) to disclose any financial relationships that have had with ineligible companies (previously defined as “commercial interests”) within the previous 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered and have been mitigated. Individuals who refuse to disclose financial relationships may not participate in an IAS–USA CME activity. The **ACCME defines ineligible companies** as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” Below are the financial interests that faculty members of this course have had within the past 24 months. View the [Faculty Financial Disclosure Policy](#).

VIRTUAL – DECEMBER 8, 2022

Course Presenters	
Roger Bedimo, MD Professor of Medicine University of Texas Southwestern Medical Center VA North Texas Health Care System Dallas, Texas	Dr Bedimo has received research funding from ViiV Healthcare and Merck & Co., and has served on the scientific advisory board for ViiV Healthcare, Merck & Co., Gilead Sciences, and Theratechnologies. (12/05/22)
Jill Blumenthal, MD, MAS Associate Professor of Medicine University of California San Diego	Dr. Blumenthal has received research support paid to her institution from Gilead Sciences, Inc. (Updated 11/28/22)
Marina Caskey, MD Weill Cornell Medicine Rockefeller University Professor of Clinical Investigation New York, New York	Dr Caskey has served on the scientific advisory board for Gilead Sciences, Inc. (12/05/22)
Susan Cu-Uvin, MD Professor Obstetrics, Gynecology, and Medicine The Warren Alpert Medical School Brown University Providence, Rhode Island	Dr Cu-Uvin receives royalties from UpToDate. (12/05/22)
Michael S. Saag, MD Professor of Medicine, Emeritus University of Alabama at Birmingham	Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc and ViiV Healthcare. Dr Saag serves as a consultant for TFF Pharmaceuticals and AmericanGene Technologies. (Updated 11/28/22)
Melanie A. Thompson, MD Thacker & Thompson, MD Atlanta, Georgia	Dr Thompson has received funding and support awarded to her institution from Bristol Myers Squibb, Cepheid Inc, Cytodyne Inc, Frontier Biotechnologies, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dohme, and ViiV Healthcare. She has served as chair of an independent data monitoring committee for Excision Biotherapeutics. (Updated 12/05/22)
IAS–USA CME Planners and Reviewers	
Constance A. Benson, MD Professor of Medicine and Global Public Health Divisions of Infectious Diseases and Global Public Health ID Training Program Director Director, Antiviral Research Center PI/Director, HIV/AIDS Clinical Trials Unit University of California San Diego	Dr Benson has served on advisory and data safety monitoring boards for GlaxoSmithKline/ViiV Healthcare, received research grants awarded to her institution from Gilead Sciences, Inc., and serves as a consultant to NDA Partners, LLC. (Updated 09/27/22)
Paul A. Volberding, MD Professor of Medicine Co-Director, Center for AIDS Research Director, AIDS Research Institute University of California San Francisco San Francisco, California	Dr Volberding has served on data and safety monitoring boards for Merck & Co, Inc. (Updated 05/31/22)
Donna M. Jacobsen Executive Director/President IAS–USA	Ms Jacobsen has no relevant financial affiliations with ineligible companies to disclose. (Updated 06/07/22)

IAS–USA Boards

The nonstaff members of the [IAS–USA Scientific Advisory Board](#) and [Governance Board](#) are not compensated for their roles in governing and overseeing the IAS–USA and content development. Please see the About page on the IAS–USA website for information about board members and a link to up-to-date financial disclosure information.